Vivani Medical (NASDAQ:VANI) Stock: Insider Gregg Williams Acquires 48,100 Shares

Vivani Medical, Inc. (NASDAQ:VANI – Get Free Report) Director Gregg Williams purchased 48,100 shares of the stock in a transaction that occurred on Friday, November 13th. The shares were bought at an average cost of $0.99 per share, for a total transaction of $47,619.00. Following the acquisition, the director owned 36,960,836 shares of the company’s stock, valued at approximately $36,591,227.64. The trade was a 0.13% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Vivani Medical Price Performance

Shares of VANI stock opened at $1.01 on Monday. The stock’s 50-day moving average price is $1.18 and its 200 day moving average price is $1.24. The stock has a market capitalization of $91.11 million, a PE ratio of -3.16 and a beta of 2.51. Vivani Medical, Inc. has a 52-week low of $0.80 and a 52-week high of $1.66.

Vivani Medical (NASDAQ:VANI – Get Free Report) last posted its quarterly earnings data on Wednesday, November 11th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, October 2nd. Wall Street Zen lowered shares of Vivani Medical from a “hold” rating to a “sell” rating in a research report on Sunday. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $3.75.

Get Our Latest Analysis on Vivani Medical

Vivani Medical Company Profile

(Get Free Report)

Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.

See Also

Insider Buying and Selling by Quarter for Vivani Medical (NASDAQ:VANI)

Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.